Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stock

Benitec Biopharma Limited (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 10,215 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $11.24 per share, with a total value of $114,816.60. Following the completion of the transaction, the director directly owned 9,546,875 shares of the company’s stock, valued at $107,306,875. This trade represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Suvretta Capital Management, L also recently made the following trade(s):

• On Monday, December 22nd, Suvretta Capital Management, L purchased 19,542 shares of Benitec Biopharma stock. The stock was acquired at an average cost of $12.08 per share, with a total value of $236,067.36.
• On Friday, December 19th, Suvretta Capital Management, L bought 16,384 shares of Benitec Biopharma stock. The stock was acquired at an average price of $11.48 per share, for a total transaction of $188,088.32.
• On Friday, November 7th, Suvretta Capital Management, L bought 1,481,481 shares of Benitec Biopharma stock. The shares were bought at an average cost of $13.50 per share, with a total value of $19,999,993.50.

Benitec Biopharma Stock Up 7.4%

BNTC opened at $12.35 on Tuesday. The firm has a market capitalization of $418.17 million, a P/E ratio of -10.21 and a beta of 0.20. The stock has a fifty day moving average of $13.81 and a 200-day moving average of $13.46. Benitec Biopharma Limited has a 12-month low of $9.70 and a 12-month high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.13. On average, analysts expect that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citizens Jmp raised their price objective on shares of Benitec Biopharma from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Wednesday, October 8th. Wall Street Zen raised Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Citigroup reaffirmed an “outperform” rating on shares of Benitec Biopharma in a report on Tuesday, November 4th. Finally, HC Wainwright set a $32.00 price target on Benitec Biopharma and gave the company a “buy” rating in a report on Monday, November 24th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. MYDA Advisors LLC raised its holdings in Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock worth $677,000 after acquiring an additional 2,000 shares in the last quarter. AWM Investment Company Inc. raised its holdings in Benitec Biopharma by 35.2% in the 1st quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock valued at $1,795,000 after acquiring an additional 35,950 shares during the period. Infinitum Asset Management LLC raised its holdings in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after acquiring an additional 915,000 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Benitec Biopharma during the first quarter worth approximately $597,000. Finally, Geode Capital Management LLC increased its position in Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock worth $4,859,000 after buying an additional 181,391 shares during the period. 52.19% of the stock is owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.